The risk of readmission within 30 days of heart failure hospitalisation is reduced by a quarter for patients receiving sacubitril/valsartan compared with those receiving enalapril, an analysis of PARADIGM-HF trial data shows.
The American Heart Association has published a scientific statement that provides a comprehensive list of drugs, including complementary/alternative medications, that may cause or exacerbate heart failure.
Donor cardiac troponin I level is not associated with intermediate-term mortality, cardiac allograft vasculopathy or primary graft failure in patients receiving heart transplants, US researchers report.
Patients hospitalised with acute heart failure who achieve good haemoconcentration in addition to a robust diuretic response are unlikely to be rehospitalised within the following 2 months, research suggests.
Temporal increases in high-sensitivity cardiac troponin T are associated with a significantly increased risk of coronary heart disease, heart failure and death among people initially free from cardiovascular disease, US study data show.
The European Society of Cardiology, with special contribution from the Heart Failure Association, has published a complete revision of its “Guidelines for the diagnosis and treatment of acute and chronic heart failure”.
US researchers have found evidence that impaired left ventricular filling in patients with chronic obstructive pulmonary disease and emphysema is caused by reduced left ventricular preload due to upstream pulmonary causes, as opposed to intrinsic diastolic dysfunction.
Use of biventricular rather than conventional right ventricular pacing results in better clinical outcomes in patients who have heart failure with atrioventricular block and left ventricular systolic dysfunction, show the results of BLOCK HF.
Meta-analysis findings question whether beta-blocker treatment remains effective in patients who have heart failure with reduced left ventricular ejection fraction if they also have atrial fibrillation.
Any benefit of dual blockade of the renin angiotensin system is limited to its effects on surrogate endpoints, and outweighed by an excessive risk for adverse events such as hypotension, hyperkalemia, and renal failure, argue hypertension experts.